Joint Bone SpinePub Date : 2026-10-31DOI: 10.1016/j.jbspin.2026.106156
Timothy Sh Kwok, Mohammad Movahedi, Angela Cesta, Pooneh Akhavan, J Carter Thorne, Janet Pope, Arthur Lau, Reza Mirza, Elliott Hepworth, Andrew Chow, Sibel Zehra Aydin, Bindee Kuriya
{"title":"Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI).","authors":"Timothy Sh Kwok, Mohammad Movahedi, Angela Cesta, Pooneh Akhavan, J Carter Thorne, Janet Pope, Arthur Lau, Reza Mirza, Elliott Hepworth, Andrew Chow, Sibel Zehra Aydin, Bindee Kuriya","doi":"10.1016/j.jbspin.2026.106156","DOIUrl":"https://doi.org/10.1016/j.jbspin.2026.106156","url":null,"abstract":"<p><strong>Objective: </strong>To determine the prevalence and factors associated with coexisting gout in rheumatoid arthritis (RA) and evaluate whether concomitant gout is associated with worse RA disease activity.</p><p><strong>Methods: </strong>We conducted a retrospective study of RA patients enrolled in the Ontario Best Practices Research Initiative, a multicentre real-world cohort across Ontario, Canada. Coexisting gout was defined by patient- or physician-reported diagnosis or xanthine oxidase inhibitor use. Multivariable logistic regression identified factors associated with coexisting gout and the impact of gout on oral glucocorticoid (GC) use. The association between baseline gout and longitudinal RA disease activity (Clinical Disease Activity Index, CDAI ≤10) was examined using mixed-effects logistic regression at 24-months, adjusting for prespecified confounders.</p><p><strong>Results: </strong>Among 3,703 RA patients, 113 (3.1%) had coexisting gout with mean (SD) age of 66.1 (8.7) years and 52.2% were female. Coexisting gout was associated with older age (OR 1.05 per year), obesity (OR 1.67), cardiovascular disease or hypertension (OR 1.95) and diuretic use (OR 1.68), while female sex was inversely associated (OR 0.31). CDAI scores were similar between patients with and without gout at baseline (18.3±12.5 vs 20.2±13.5) and at 12-months (10.9±9.8 vs 11.0±10.4). After adjustment, baseline coexisting gout was neither significantly associated with oral GC use at 12-months (OR 1.73, 95% CI: 0.96-3.13) or the attainment of CDAI low disease activity/remission by 24-months (OR 1.19, 95% CI: 0.72-1.97).</p><p><strong>Conclusion: </strong>In this large real-world RA cohort, coexisting gout was uncommon and associated with traditional gout risk factors but did not statistically influence oral GC use or RA treatment target attainment.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106156"},"PeriodicalIF":5.0,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joint Bone SpinePub Date : 2026-10-27DOI: 10.1016/j.jbspin.2026.106154
Serge Perrot
{"title":"Are Cannabis and Cannabinoids a Valid Treatment Option in Patients with Rheumatic Diseases? A narrative review.","authors":"Serge Perrot","doi":"10.1016/j.jbspin.2026.106154","DOIUrl":"https://doi.org/10.1016/j.jbspin.2026.106154","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate current evidence regarding the efficacy and safety of cannabis and cannabinoids in patients with rheumatic diseases.</p><p><strong>Methods: </strong>A narrative review was conducted based on a search for studies published between 2000 and 2026 evaluating cannabinoid therapies in rheumatic diseases.</p><p><strong>Results: </strong>We identified 17 preclinical studies on the mechanisms of action of cannabis and 43 clinical studies published between 2000 and 2026, including randomized trials, observational studies and systematic reviews. We identified two articles on rheumatoid arthritis, 10 on osteoarthritis (2 reviews and 8 clinical studies), 28 on fibromyalgia (9 reviews, 7 randomized control trials, 12 clinical studies), one on psoriatic arthritis, and one on systemic sclerosis. The evidence of an effect of cannabinoids was strongest for fibromyalgia and limited for rheumatoid arthritis and osteoarthritis. Most studies reported improvements in pain and sleep quality. Globally, cannabinoids were well tolerated.</p><p><strong>Conclusion: </strong>Some studies suggest short-term symptomatic benefits of cannabinoid-based therapies, particularly in fibromyalgia, but the findings are inconsistent and limited by small samples, heterogeneous formulations, and risk of bias. Current evidence is insufficient to support routine clinical use or recommendations in rheumatic diseases.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106154"},"PeriodicalIF":5.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sleep disorders in patients with systemic sclerosis: A systematic review and meta-analysis.","authors":"Yannick Laurent Tchenadoyo Bayala, Ismael Ayouba Tinni, Charles Sougué, Fulgence Kaboré, Wendlassida Joelle Stéphanie Zabsonré-Tiendrebeogo, Dieu-Donné Ouédraogo","doi":"10.1016/j.jbspin.2026.106152","DOIUrl":"10.1016/j.jbspin.2026.106152","url":null,"abstract":"<p><strong>Background: </strong>Systemic sclerosis is a rare autoimmune disease associated with substantial morbidity and reduced quality of life. Sleep disturbance has been reported with variable frequency in patients with systemic sclerosis, though its prevalence remains incompletely characterised.</p><p><strong>Objective: </strong>This systematic review and meta-analysis aimed to estimate the pooled prevalence of sleep disorders in patients with systemic sclerosis.</p><p><strong>Methods: </strong>Six databases were searched up to 15th February 2026 without language restriction. Studies reporting sleep outcomes in adults with systemic sclerosis were eligible. Prevalence estimates were pooled using a logit transformation with a random-effects model and Hartung-Knapp correction. Heterogeneity was assessed using the I<sup>2</sup> statistic. Publication bias was evaluated with Egger's test and the trim-and-fill method. This review was registered in PROSPERO (CRD420251152354).</p><p><strong>Results: </strong>Twenty-three studies totalling 1487 patients were included across all analyses. Eleven studies (820 patients) contributed to the primary meta-analysis of poor sleep quality assessed by the Pittsburgh Sleep Quality Index. The pooled prevalence of poor sleep quality was 76.49% (95% CI 66.62 to 84.13%), with moderate to substantial heterogeneity (I<sup>2</sup>=70.1%) and a 95% prediction interval of 49.66 to 91.47%, indicating that the true prevalence may range from approximately half to nearly all patients across different SSc populations. Five studies (346 patients) contributed to the obstructive sleep apnea meta-analysis, yielding a pooled prevalence of 40.30% (95% CI 25.56 to 57.04%, I<sup>2</sup>=71.8%) with a 95% prediction interval of 13.95 to 73.75%. Five additional studies were included in a qualitative synthesis only, and three randomised controlled trials addressed sleep interventions. Egger's test identified possible funnel plot asymmetry. After trim-and-fill adjustment, four studies were imputed and the corrected estimate was 69.62% (95% CI 57.33 to 79.63%), somewhat lower than the primary estimate, suggesting that the primary estimate may be modestly influenced by publication bias. The certainty of evidence was rated as low according to GRADE.</p><p><strong>Conclusion: </strong>Available evidence suggests that sleep disorders may affect approximately three quarters of patients with systemic sclerosis when assessed by the PSQI, and obstructive sleep apnea may affect more than one third when evaluated by objective tools. These estimates carry low GRADE certainty and wide prediction intervals, and should not be interpreted as definitive prevalence figures. Larger prospective studies and well-powered randomised trials are needed to establish more precise estimates and to evaluate targeted sleep interventions in this population.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106152"},"PeriodicalIF":5.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"JAK inhibitor cycling shows higher drug retention than biologic switching following first JAK inhibitor failure in rheumatoid arthritis.","authors":"Ming-Hsuan Tsai, Heh-Shiang Sheu, Kai-Chun Wang, Ping-Hsuan Kuo, Yi-Ming Chen, Wen-Nan Huang, Meng-Chieh Shih, Ling-Ying Lu, Wei-Sheng Chen, Hsien-Tzung Liao, Chien-Chih Lai, Yen-Po Tsao, Yi-Syuan Sun, Hung-Cheng Tsai, Tsu-Yi Hsieh, Hsin-Hua Chen, Kuo-Lung Lai, Ching-Tsai Lin, Chia-Wei Hsieh, Jui-Cheng Tseng, Jui-Chieh Hu, Li-Fong Wang, Ling-Jung Yen, Ming-Han Chen","doi":"10.1016/j.jbspin.2026.106150","DOIUrl":"10.1016/j.jbspin.2026.106150","url":null,"abstract":"<p><strong>Objectives: </strong>Evidence guiding treatment sequencing after JAK inhibitor failure in rheumatoid arthritis remains limited. This study compared treatment persistence and clinical effectiveness between JAK inhibitor cycling and biologic switching after discontinuation of an initial JAK inhibitor due to inadequate response.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study included only patients who discontinued their first JAK inhibitor due to inadequate response. The primary outcome was 12-month drug retention. Inverse probability of treatment weighting was used to balance baseline characteristics. Secondary outcomes included reasons for discontinuation within 12 months and clinical effectiveness at 6 months, assessed using the response criteria of the European Alliance of Associations for Rheumatology.</p><p><strong>Results: </strong>Among the 186 patients, 44 (23.7%) cycled to another JAK inhibitor and 142 (76.3%) switched to biologic therapy. After adjustment using inverse probability of treatment weighting, cycling was associated with significantly higher 12-month drug retention than switching (hazard ratio, 0.27; 95% CI, 0.10-0.71; P<0.01). This difference was mainly driven by fewer discontinuations owing to insufficient efficacy. Concomitant glucocorticoid use independently predicted improved retention (adjusted hazard ratio, 0.50; 95% CI, 0.28-0.92; P<0.05). At 6 months, good or moderate response rates were not significantly different between groups (78.6% vs. 62.0%), although multivariable analysis favored cycling (odds ratio, 3.41; 95% CI, 1.03-11.29; P<0.05).</p><p><strong>Conclusions: </strong>Among patients with rheumatoid arthritis who had an inadequate response to their first JAK inhibitor, cycling to another JAK inhibitor was associated with superior 12-month drug retention with comparable short-term clinical effectiveness.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106150"},"PeriodicalIF":5.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joint Bone SpinePub Date : 2026-10-10DOI: 10.1016/j.jbspin.2026.106146
Alexandre Meynard, Pascale Vergne-Salle
{"title":"Septic arthritis of the left L3-L4 facet joint.","authors":"Alexandre Meynard, Pascale Vergne-Salle","doi":"10.1016/j.jbspin.2026.106146","DOIUrl":"10.1016/j.jbspin.2026.106146","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106146"},"PeriodicalIF":5.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joint Bone SpinePub Date : 2026-10-10DOI: 10.1016/j.jbspin.2026.106147
Joanna Kedra, Aya Ajrouche, Yann de Rycke, Octave Guinebretiere, Julien Kirchgesner, Elisabeth Maillart, Florence Tubach, Bruno Fautrel
{"title":"Risk of demyelinating events associated with TNF-inhibitors compared with conventional synthetic disease modifying anti-rheumatic drugs in rheumatoid arthritis: Results from the French National Health Data System.","authors":"Joanna Kedra, Aya Ajrouche, Yann de Rycke, Octave Guinebretiere, Julien Kirchgesner, Elisabeth Maillart, Florence Tubach, Bruno Fautrel","doi":"10.1016/j.jbspin.2026.106147","DOIUrl":"10.1016/j.jbspin.2026.106147","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the risk of demyelinating events of TNF-inhibitors compared to conventional synthetic disease modifying anti-rheumatic drugs, in rheumatoid arthritis in real life setting.</p><p><strong>Methods: </strong>In this nationwide population-based cohort study conducted in the French National Health Data System, adult patients with rheumatoid arthritis, with no history of demyelinating event, naïve to conventional treatments and TNF-inhibitors, were included at conventional treatment initiation between 2008 and 2022 and followed until December 31, 2023. The primary endpoint was the occurrence of an incident coded demyelinating event (central or peripheral), identified by International Classification of Diseases (10th revision) codes. The association with TNF-inhibitors was assessed using a marginal structural Cox model weighted by inverse probability of treatment weights, with time-dependent exposure.</p><p><strong>Results: </strong>Overall, 214,892 patients with rheumatoid arthritis (70.6% women, median age 58.8 years) incident users of conventional treatments were included, with a median follow-up time of 7.4 years; among them, 40,139 patients initiated a TNF-inhibitor during follow-up. A total of 562 coded demyelinating events occurred under treatments exposure between 2008 and 2023. The weighted cumulative incidence of demyelinating events at 10 years was 0.32% (95%CI 0.29-0.36) with conventional treatments, and 0.50% (95%CI 0.36-0.63) with TNF-inhibitors. Exposure to TNF-inhibitors was statistically significantly associated with an increased risk of coded demyelinating events compared with conventional treatments, hazard ratio (HR) 1.47 (95% CI, 1.11-1.95).</p><p><strong>Conclusions: </strong>Demyelinating events are rare in patients with rheumatoid arthritis. This study found a statistically significant increased risk of coded demyelinating event associated with TNF-inhibitors exposure compared with conventional treatments.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106147"},"PeriodicalIF":5.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joint Bone SpinePub Date : 2026-10-10DOI: 10.1016/j.jbspin.2026.106145
Arno Wahler, Sandra Guignard, Gaëlle Quéreux, Olivier Carpentier, Diane Marcé, Elise Dietrich, Matthieu Saintvoirin, Florent Amatore, Ewa Hainaut, Marine De Vicq De Cumptich, Claudia Béjar Ardiles, Olivier Dereure, Marie Beylot-Barry, Saskia Ingen-Housz-Oro
{"title":"Inflammatory rheumatic diseases under mogamulizumab: A multicenter series of 11 cases.","authors":"Arno Wahler, Sandra Guignard, Gaëlle Quéreux, Olivier Carpentier, Diane Marcé, Elise Dietrich, Matthieu Saintvoirin, Florent Amatore, Ewa Hainaut, Marine De Vicq De Cumptich, Claudia Béjar Ardiles, Olivier Dereure, Marie Beylot-Barry, Saskia Ingen-Housz-Oro","doi":"10.1016/j.jbspin.2026.106145","DOIUrl":"10.1016/j.jbspin.2026.106145","url":null,"abstract":"<p><strong>Background: </strong>Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody for mycosis fungoides (MF) and Sézary syndrome (SS), can trigger immune-mediated complications, such as rashes or endocrine disorders. Rheumatological manifestations are rare.</p><p><strong>Objectives: </strong>To describe cases of inflammatory rheumatism (IR) induced or worsened by MOGA in MF/SS patients.</p><p><strong>Methods: </strong>A retrospective study collected cases of IR (polymyalgia rheumatica [PMR], rheumatoid arthritis [RA], spondylarthritis, or unclassified IR) in MF/SS patients treated with MOGA across centers of the French Cutaneous Lymphomas Group. Clinical, biological, and imaging data were analyzed.</p><p><strong>Results: </strong>Eleven patients (7 men, 4 women; median age: 72 years) developed IR during (10/11) or soon after (1/11) MOGA treatment. Symptoms included joint pain, stiffness, and functional impairment. All had biological inflammatory syndrome, synovitis on ultrasound, and no autoantibodies. PET-CT confirmed hypermetabolism consistent with intense joint inflammation (SUV=8.0). Management with systemic corticosteroids±methotrexate led to remission in most cases. MOGA had to be discontinued in 8 patients, with lymphoma control maintained in 6.</p><p><strong>Conclusions: </strong>MOGA may induce disabling IR, potentially via CCR4+ regulatory T-cell depletion. Early recognition and treatment with corticosteroids±methotrexate are essential, though MOGA discontinuation may be required.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106145"},"PeriodicalIF":5.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}